The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Bipolar Disorder Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Bipolar disorder, also known as manic depression, is a mental disorder that could lead to periods of depression and elevated mood. The treatment of bipolar disorder includes psychotherapy as well as medications such as mood stabilizers and antipsychotics.
The global Bipolar Disorder Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Bipolar Disorder Drugs in various end use industries. The expanding demands from the Hospital, Clinics and Others,, are propelling Bipolar Disorder Drugs market. Mood Stabilizers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antipsychotic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bipolar Disorder Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bipolar Disorder Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bipolar Disorder Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bipolar Disorder Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bipolar Disorder Drugs covered in this report include AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson., GlaxoSmithKline, AbbVie and Pfizer, etc.
The global Bipolar Disorder Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly
Astellas Pharma
Allergan
Johnson & Johnson.
GlaxoSmithKline
AbbVie
Pfizer
Novartis
Global Bipolar Disorder Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bipolar Disorder Drugs market, Segment by Type:
Mood Stabilizers
Antipsychotic Drugs
Antidepressant Drugs
Other Drugs
Global Bipolar Disorder Drugs market, by Application
Hospital
Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Bipolar Disorder Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Bipolar Disorder Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Bipolar disorder, also known as manic depression, is a mental disorder that could lead to periods of depression and elevated mood. The treatment of bipolar disorder includes psychotherapy as well as medications such as mood stabilizers and antipsychotics.
The global Bipolar Disorder Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Bipolar Disorder Drugs in various end use industries. The expanding demands from the Hospital, Clinics and Others,, are propelling Bipolar Disorder Drugs market. Mood Stabilizers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antipsychotic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bipolar Disorder Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bipolar Disorder Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bipolar Disorder Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bipolar Disorder Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bipolar Disorder Drugs covered in this report include AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Astellas Pharma, Allergan, Johnson & Johnson., GlaxoSmithKline, AbbVie and Pfizer, etc.
The global Bipolar Disorder Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly
Astellas Pharma
Allergan
Johnson & Johnson.
GlaxoSmithKline
AbbVie
Pfizer
Novartis
Global Bipolar Disorder Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bipolar Disorder Drugs market, Segment by Type:
Mood Stabilizers
Antipsychotic Drugs
Antidepressant Drugs
Other Drugs
Global Bipolar Disorder Drugs market, by Application
Hospital
Clinics
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Bipolar Disorder Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Bipolar Disorder Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Bipolar Disorder Drugs Market Overview
1.1 Bipolar Disorder Drugs Product Overview
1.2 Bipolar Disorder Drugs Market Segment by Type
1.2.1 Mood Stabilizers
1.2.2 Antipsychotic Drugs
1.2.3 Antidepressant Drugs
1.2.4 Other Drugs
1.3 Global Bipolar Disorder Drugs Market Size by Type
1.3.1 Global Bipolar Disorder Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Bipolar Disorder Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Bipolar Disorder Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Bipolar Disorder Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Bipolar Disorder Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Bipolar Disorder Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Bipolar Disorder Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Bipolar Disorder Drugs Sales Breakdown by Type (2018-2023)
2 Global Bipolar Disorder Drugs Market Competition by Company
2.1 Global Top Players by Bipolar Disorder Drugs Sales (2018-2023)
2.2 Global Top Players by Bipolar Disorder Drugs Revenue (2018-2023)
2.3 Global Top Players by Bipolar Disorder Drugs Price (2018-2023)
2.4 Global Top Manufacturers Bipolar Disorder Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Bipolar Disorder Drugs Market Competitive Situation and Trends
2.5.1 Bipolar Disorder Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Bipolar Disorder Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bipolar Disorder Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Bipolar Disorder Drugs Market
2.8 Key Manufacturers Bipolar Disorder Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Bipolar Disorder Drugs Status and Outlook by Region
3.1 Global Bipolar Disorder Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Bipolar Disorder Drugs Historic Market Size by Region
3.2.1 Global Bipolar Disorder Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Bipolar Disorder Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Bipolar Disorder Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Bipolar Disorder Drugs Forecasted Market Size by Region
3.3.1 Global Bipolar Disorder Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Bipolar Disorder Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Bipolar Disorder Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Bipolar Disorder Drugs by Application
4.1 Bipolar Disorder Drugs Market Segment by Application
4.1.1 Hospital
4.1.2 Clinics
4.1.3 Others
4.2 Global Bipolar Disorder Drugs Market Size by Application
4.2.1 Global Bipolar Disorder Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Bipolar Disorder Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Bipolar Disorder Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Bipolar Disorder Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Bipolar Disorder Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Bipolar Disorder Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Bipolar Disorder Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Bipolar Disorder Drugs Sales Breakdown by Application (2018-2023)
5 North America Bipolar Disorder Drugs by Country
5.1 North America Bipolar Disorder Drugs Historic Market Size by Country
5.1.1 North America Bipolar Disorder Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Bipolar Disorder Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Bipolar Disorder Drugs Sales in Value by Country (2018-2023)
5.2 North America Bipolar Disorder Drugs Forecasted Market Size by Country
5.2.1 North America Bipolar Disorder Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Bipolar Disorder Drugs Sales in Value by Country (2024-2029)
6 Europe Bipolar Disorder Drugs by Country
6.1 Europe Bipolar Disorder Drugs Historic Market Size by Country
6.1.1 Europe Bipolar Disorder Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Bipolar Disorder Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Bipolar Disorder Drugs Sales in Value by Country (2018-2023)
6.2 Europe Bipolar Disorder Drugs Forecasted Market Size by Country
6.2.1 Europe Bipolar Disorder Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Bipolar Disorder Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Bipolar Disorder Drugs by Region
7.1 Asia-Pacific Bipolar Disorder Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Bipolar Disorder Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Bipolar Disorder Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Bipolar Disorder Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Bipolar Disorder Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Bipolar Disorder Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Bipolar Disorder Drugs Sales in Value by Region (2024-2029)
8 Latin America Bipolar Disorder Drugs by Country
8.1 Latin America Bipolar Disorder Drugs Historic Market Size by Country
8.1.1 Latin America Bipolar Disorder Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Bipolar Disorder Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Bipolar Disorder Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Bipolar Disorder Drugs Forecasted Market Size by Country
8.2.1 Latin America Bipolar Disorder Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Bipolar Disorder Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Bipolar Disorder Drugs by Country
9.1 Middle East and Africa Bipolar Disorder Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Bipolar Disorder Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Bipolar Disorder Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Bipolar Disorder Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Bipolar Disorder Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Bipolar Disorder Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Bipolar Disorder Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Bipolar Disorder Drugs Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Bristol-Myers Squibb Company
10.2.1 Bristol-Myers Squibb Company Company Information
10.2.2 Bristol-Myers Squibb Company Introduction and Business Overview
10.2.3 Bristol-Myers Squibb Company Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Bristol-Myers Squibb Company Bipolar Disorder Drugs Products Offered
10.2.5 Bristol-Myers Squibb Company Recent Development
10.3 Eli Lilly
10.3.1 Eli Lilly Company Information
10.3.2 Eli Lilly Introduction and Business Overview
10.3.3 Eli Lilly Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Eli Lilly Bipolar Disorder Drugs Products Offered
10.3.5 Eli Lilly Recent Development
10.4 Astellas Pharma
10.4.1 Astellas Pharma Company Information
10.4.2 Astellas Pharma Introduction and Business Overview
10.4.3 Astellas Pharma Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Astellas Pharma Bipolar Disorder Drugs Products Offered
10.4.5 Astellas Pharma Recent Development
10.5 Allergan
10.5.1 Allergan Company Information
10.5.2 Allergan Introduction and Business Overview
10.5.3 Allergan Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Allergan Bipolar Disorder Drugs Products Offered
10.5.5 Allergan Recent Development
10.6 Johnson & Johnson.
10.6.1 Johnson & Johnson. Company Information
10.6.2 Johnson & Johnson. Introduction and Business Overview
10.6.3 Johnson & Johnson. Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Johnson & Johnson. Bipolar Disorder Drugs Products Offered
10.6.5 Johnson & Johnson. Recent Development
10.7 GlaxoSmithKline
10.7.1 GlaxoSmithKline Company Information
10.7.2 GlaxoSmithKline Introduction and Business Overview
10.7.3 GlaxoSmithKline Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 GlaxoSmithKline Bipolar Disorder Drugs Products Offered
10.7.5 GlaxoSmithKline Recent Development
10.8 AbbVie
10.8.1 AbbVie Company Information
10.8.2 AbbVie Introduction and Business Overview
10.8.3 AbbVie Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 AbbVie Bipolar Disorder Drugs Products Offered
10.8.5 AbbVie Recent Development
10.9 Pfizer
10.9.1 Pfizer Company Information
10.9.2 Pfizer Introduction and Business Overview
10.9.3 Pfizer Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Pfizer Bipolar Disorder Drugs Products Offered
10.9.5 Pfizer Recent Development
10.10 Novartis
10.10.1 Novartis Company Information
10.10.2 Novartis Introduction and Business Overview
10.10.3 Novartis Bipolar Disorder Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Novartis Bipolar Disorder Drugs Products Offered
10.10.5 Novartis Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Bipolar Disorder Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Bipolar Disorder Drugs Industrial Chain Analysis
11.4 Bipolar Disorder Drugs Market Dynamics
11.4.1 Bipolar Disorder Drugs Industry Trends
11.4.2 Bipolar Disorder Drugs Market Drivers
11.4.3 Bipolar Disorder Drugs Market Challenges
11.4.4 Bipolar Disorder Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Bipolar Disorder Drugs Distributors
12.3 Bipolar Disorder Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
